Archive for July 13th, 2009

VOLUME ALERT: Oculus Innovative Sciences (OCLS)

Oculus Innovative Sciences Inc. (Nasdaq: OCLS) shares are up more than 5 percent on volume of 37,000 shares near the open. The company this morning said OroScience will exclusively market Oculus’ Microcyn-based oral products in the U.S., Canada and European markets. Terms of the revenue-sharing agreement were not disclosed.– Mike Tarsala

Banking stocks are the premarket sector to watch (BAC, GS, C)

Several banking stocks are benefiting early Monday from noted financial bear Meredith Whitney’s bullish comments on the sector. Bank of America (NYSE: BAC) shares are up about 5 percent to $12.50 on premaket volume of 3 million shares, after the analyst said BofA is the cheapest of the banking names, based on her analysis of [...]


JA Solar Holdings Co. (Nasdaq: JASO) shares are up nearly 4 percent to $3.94 on about 10,000 premarket shares traded as of 8:30 a.m. Eastern. The company’s stock was started with a Buy rating and a $5 price target at Needham & Co., saying it is well positioned to benefit from a growing solar market [...]


Cephid (Nasdaq: CPHD) shares are up 9 percent to $9.15 on more than 4,000 premarket shares traded as of 8:30 a.m. Eastern. the molecular-diagnostics company said it has received the FDA’s OK for a new test that the company says can diagnose a bacteria linked to antibiotic-resistant infections, diarrhea and colitis within 45 minutes. – [...]

PREMARKET ALERT: Rino International (RINO)

Rino International (Nasdaq: RINO) shares are up 9 percent to $9.92 on about 7,000 premarket shares traded as of 8:20 a.m. Eastern. The China-based provider of wastewater treatment systems has been granted a Nasdaq Global Markets listing. — Mike Tarsala


SanDisk Corp. (Nasdaq: SNDK) shares are up about 2.5 percent to $14.85 on nearly 10,000 shares traded. Thomas Weisel this morning upgraded the stock to an Overweight from a Market Weight rating.


OSI Pharmaceuticals Inc. (Nasdaq: OSIP) shares are up 9 percent to $31 on premarket volume of about 13,500 shares as of 8:15 Eastern. The company announced new data from its Phase III Saturn study of Tarceva. The drug improved overall survival when used immediately after initial chemotherapy in lung cancer patients. — Mike Tarsala


CardioNet Inc. (Nasdaq: BEAT) shares are down 30 percent to $6.16 on 128,000 premarket shares traded as of 8:15 a.m. Eastern. It is one of the most active stocks in the early premarket. The company this morning announced a reimbursement reduction from one of its key customers, and withdrew its previously stated fiscal 2009 guidance. — [...]